Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Combination Treatments Will Provide Significant Opportunity for Companies that Offer Multiple Injectable Types, According to Findings from Decision Resources Group
BURLINGTON, Mass., Feb. 11, 2014 /PRNewswire/ -- Decision Resources Group finds that high aesthetic consciousness and growing product availability will drive market growth in the markets for facial injectables in both Europe and the United States. Product approval regulations are less stringent in Europe, so more many new products will be introduced there. However, despite wider product availability, European economic concerns will result in slower revenue growth than in the U.S.
The low entry barriers to the European market have led to an influx of smaller competitors and a high number of similar products. However, larger, well-established companies have held on to their majority market share because these players generally have attained Food and Drug Administration (FDA) approval in the U.S. and are thus associated with proven clinical safety and efficacy. In contrast to the strong competition in Europe, the U.S. market has seen a number of mergers and acquisitions recently, which has led to increased consolidation and growing market shares among larger players. Allergan remained the leader of both the U.S. and European markets in 2013, although its dominance of the U.S. market was much more established, given the lower competition in this region.
"The prominence of the company's BOTOX brand has supported Allergan's dominance in the botulinum toxin (BTX) segment," said Decision Resources Group Analyst David Lee. "The company has also seen success with its JUVEDERM dermal filler, which it frequently bundles with BOTOX injectables for use in combination treatments. Allergan is also expected to launch the JUVEDERM Voluma in the U.S. in the near future; this is the only product that has received FDA approval for correcting volume loss in cheeks. This product therefore differentiates itself easily from competitors' offerings and will see significant adoption."
Decision Resources Group's US Markets for Facial Injectables 2014 and European Markets for Facial Injectables 2014 reports include unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for BTX and dermal fillers in the United States, France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.